Abstract
QS-21, a saponin extracted from the tree Quillaja saponaria Molina, is a vaccine adjuvant which has been shown to elicit robust antibody and cell-mediated immune responses in a variety of preclinical and clinical studies [1]. Its purification from the natural source is a lengthy and difficult process. The commercially available saponin mixture Quil-A® is a fraction of the bark extract containing a variety of saponins, including QS-21. In order to facilitate access to QS-21 at laboratory-scale amounts, we propose here a method of purification of QS-21 starting from Quil-A®. In addition, we describe a protocol to appropriately formulate QS-21 into cholesterol-containing, neutral liposomes which are known to decrease QS-21’s hemolytic activity while retaining the adjuvant effect. Methods for the physicochemical characterization of purified QS-21 and of the QS-21/liposome formulations are also described.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
https://clinicaltrials.gov/ct2/results?term=QS-21&Search=Search.
Ragupathi G, Gardner JR, Livingston PO, Gin DY (2011) Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer. Expert Rev Vaccines 10:463–470
Dalsgaard (1978) A study of the isolation and characterization of the saponin Quil-A®. Evaluation of its adjuvant activity, with a special reference to the application in the vaccination of cattle against foot-and-mouth disease. Acta Vet Scand Suppl 69:7–40
Kensil CR, Patel U, Lennick M, Marciani D (1991) Separation and characterization of saponins with adjuvant activity from Quillaja Saponaria Molina cortex. J Immunol 146:431–437
Kensil CR (2001) Saponin adjuvant composition. US Patent 6231859 B1
Fernandez-Tejada A, Chea EK, George C, Gardner JR, Livingston PO, Ragupathi G, Tan DS, Gin DY (2014) Design, synthesis, and immunologic evaluation of vaccine adjuvant conjugates based on QS-21 and tucaresol. Bioorg Med Chem 22:5917–5923
Kensil CR, Kammer R (1998) QS-21: a water-soluble triterpene glycoside adjuvant. Expert Opin Investig Drugs 7:1475–1482
Cleland JL, Kensil CR, Lim A, Jacobsen NE, Basa L, Spellman M, Wheeler DA, Wu JY, Powell MF (1996) Isomerization and formulation stability of the vaccine adjuvant QS-21. J Pharm Sci 85:22–28
Lorent JH, Quetin-Leclercq J, Mingeot-Leclercq MP (2014) The amphiphilic nature of saponins and their effects on artificial and biological membranes and potential consequences for red blood and cancer cells. Org Biomol Chem 12:8803–8822
Myschik J, Lendemans DG, McBurney WT, Demana PH, Hook S, Rades T (2006) On the preparation, microscopic investigation and application of iscoms. Micron 37:724–734
Sanders MT, Brown LE, Deliyannis G, Pearse MJ (2005) Iscom-based vaccines: the second decade. Immunol Cell Biol 83:119–128
Seeman P (1974) Ultrastructure of membrane lesions in immune lysis, osmotic lysis and drug-induced lysis. Fed Proc 33:2116–2124
Vandepapeliere P (2013) Vaccine composition comprising a saponin adjuvant-Patent EP 2364721 B1.
Garçon NM Friede M (2007) Vaccines containing a saponin and a sterol. Patent ep 0 955 059 b1
Kensil CR (2000) QS-21 adjuvant. In: Vaccine adjuvants: preparation methods and research protocols, Methods in Molecular Medicine, edited by O’HaganDT, Humana press, New Jersey
Acknowledgment
The authors thank Maude Marti Favre, Virginie Jakob, and Geraldine Frank for their excellent technical assistance.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media New York
About this protocol
Cite this protocol
Brunner, L., Barnier-Quer, C., Collin, N. (2017). QS-21 Adjuvant: Laboratory-Scale Purification Method and Formulation Into Liposomes. In: Fox, C. (eds) Vaccine Adjuvants. Methods in Molecular Biology, vol 1494. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-6445-1_5
Download citation
DOI: https://doi.org/10.1007/978-1-4939-6445-1_5
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-6443-7
Online ISBN: 978-1-4939-6445-1
eBook Packages: Springer Protocols